** Shares of medical software firm Omnicell OMCL.O rise 10.3% to $30.15
** OMCL expects 2025 adj. profit forecast in the range of $1.30 to $1.65 per share, compared with previously projected range of $1 to $1.65
** "The updated guidance ranges assume that the potential tariff rate on imports from China returns to 145% after the temporary 90-day reduction period," the company says
** Each 25% reduction below a 145% tariff rate, beginning August 12, represents an expected about $2 million reduction of the impact from the duties on profitability in 2025 - company
** Company expects Q2 adj profit between 24 cents and 34 cents per share vs analysts' estimates 30 cents - data compiled by LSEG
** Company also approved a $75 million stock repurchase program
** Including session's moves, stock down 33.9% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。